UY33533A - siRNA DIRIGIDO AL VEGFA Y A MÉTODOS DE TRATAMIENTO IN VIVO - Google Patents
siRNA DIRIGIDO AL VEGFA Y A MÉTODOS DE TRATAMIENTO IN VIVOInfo
- Publication number
- UY33533A UY33533A UY0001033533A UY33533A UY33533A UY 33533 A UY33533 A UY 33533A UY 0001033533 A UY0001033533 A UY 0001033533A UY 33533 A UY33533 A UY 33533A UY 33533 A UY33533 A UY 33533A
- Authority
- UY
- Uruguay
- Prior art keywords
- vegfa
- syrna
- aimed
- treatment methods
- vivo treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
Abstract
El factor de crecimiento endotelial vascular A(VEGFA) es una señal química producida por células que estimulan el crecimiento de nuevos vasos sanguíneos, y la sobreexpresión del VEGFA puede llevar a condiciones fisiológicas no deseadas. Mediante la identificación del nuevo siRNA y modificaciones que mejoran la habilidad de silenciar dicho siRNA in vivo, se han inventado composiciones y métodos terapéuticos para tratar los problemas asociados con dicha sobreexpresión.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36838510P | 2010-07-28 | 2010-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33533A true UY33533A (es) | 2012-02-29 |
Family
ID=45527345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033533A UY33533A (es) | 2010-07-28 | 2011-07-27 | siRNA DIRIGIDO AL VEGFA Y A MÉTODOS DE TRATAMIENTO IN VIVO |
Country Status (16)
Country | Link |
---|---|
US (2) | US8546349B2 (es) |
EP (1) | EP2598639A4 (es) |
JP (1) | JP2013539456A (es) |
KR (1) | KR20130095737A (es) |
CN (1) | CN103068981A (es) |
AR (1) | AR082411A1 (es) |
AU (1) | AU2011282902B2 (es) |
BR (1) | BR112013001918A2 (es) |
CA (1) | CA2804847A1 (es) |
CL (1) | CL2013000237A1 (es) |
MX (1) | MX2013000986A (es) |
RU (1) | RU2013102545A (es) |
TW (1) | TW201219041A (es) |
UY (1) | UY33533A (es) |
WO (1) | WO2012015775A2 (es) |
ZA (1) | ZA201300531B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2015133252A (ru) | 2013-01-08 | 2017-02-10 | Бенитек Байофарма Лимитед | Лечение возрастной макулярной дегенерации |
EP2986599A1 (en) | 2013-04-17 | 2016-02-24 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
TWI496595B (zh) * | 2013-06-07 | 2015-08-21 | Univ Nat Taiwan Ocean | 製備魚類核醣核酸試劑之方法 |
EP3138293A4 (en) * | 2014-04-29 | 2017-05-24 | Microsoft Technology Licensing, LLC | Encoder-side decisions for sample adaptive offset filtering |
EP3294880A4 (en) * | 2015-05-15 | 2018-12-26 | Dharmacon, Inc. | Synthetic single guide rna for cas9-mediated gene editing |
WO2017173327A1 (en) * | 2016-03-31 | 2017-10-05 | The Schepens Eye Research Institute, Inc. | Endomucin inhibitor as an anti-angiogenic agent |
GB201802404D0 (en) * | 2018-02-14 | 2018-03-28 | Univ Malta | Methods |
EP3775217A4 (en) * | 2018-04-10 | 2022-06-01 | Ottawa Hospital Research Institute | MICRORNA-BASED COMPOSITIONS AND METHODS OF TREATMENT OF DISEASES |
JP2022546415A (ja) * | 2019-09-06 | 2022-11-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 治療薬の核酸媒介性送達 |
IL295445A (en) * | 2020-02-10 | 2022-10-01 | Alnylam Pharmaceuticals Inc | Preparations and methods for silencing vegf-a expression |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731294A (en) | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
US6410322B1 (en) | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
US6306829B1 (en) | 1995-12-08 | 2001-10-23 | Hybridon, Inc. | Modified VEGF oligonucleotides for treatment of skin disorders |
US5641756A (en) | 1993-07-27 | 1997-06-24 | Hybridon, Inc. | Modified VEGF oligonucleotides |
EP0769552A4 (en) | 1994-06-27 | 1997-06-18 | Toagosei Co Ltd | ANTISENSE NUCLEIC ACID COMPOUND |
US5830879A (en) | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
WO1997021808A1 (en) | 1995-12-08 | 1997-06-19 | Hybridon, Inc. | Modified vegf antisense oligonucleotides |
CA2251945A1 (en) | 1996-04-17 | 1997-10-23 | Aronex Pharmaceuticals, Inc. | Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression |
AU6237198A (en) | 1996-12-19 | 1998-07-15 | Isis Pharmaceuticals, Inc. | Large-scale purification of full length oligonucleotides by solid-liquid affinity extraction |
JPH1142091A (ja) | 1997-07-25 | 1999-02-16 | Toagosei Co Ltd | アンチセンス核酸化合物 |
AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
WO1999063975A2 (en) | 1998-06-10 | 1999-12-16 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | A method for stimulating the immune system |
HUP0104302A3 (en) | 1998-11-06 | 2002-11-28 | Abbott Gmbh & Co Kg | Inhibition of the formation of vascular hyperpermeability |
WO2002031141A2 (en) | 2000-10-13 | 2002-04-18 | Institut De Cardiologie De Montreal | Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof |
AU2002305236A1 (en) | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent |
US20070021360A1 (en) | 2001-04-24 | 2007-01-25 | Nyce Jonathan W | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase |
WO2003070910A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US7517864B2 (en) * | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
EP1390385A4 (en) | 2001-05-29 | 2004-11-24 | Sirna Therapeutics Inc | MODULATION OF DISEASES AND DISEASES OF THE FEMALE REPRODUCTION SYSTEM BASED ON NUCLEIC ACID |
FR2832154B1 (fr) | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
US20100113307A1 (en) | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA targeting vascular endothelial growth factor (VEGF) |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
EP2314691A3 (en) | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
US20040191818A1 (en) * | 2003-02-26 | 2004-09-30 | O'toole Margot Mary | Compositions and methods for diagnosing and treating autoimmune diseases |
WO2004090105A2 (en) * | 2003-04-02 | 2004-10-21 | Dharmacon, Inc. | Modified polynucleotides for use in rna interference |
JP2008167739A (ja) * | 2006-06-14 | 2008-07-24 | National Institute Of Advanced Industrial & Technology | Rna干渉効果が高い修飾型二本鎖rna |
WO2008036825A2 (en) * | 2006-09-22 | 2008-03-27 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by rna interference |
WO2008045576A2 (en) * | 2006-10-12 | 2008-04-17 | Yijia Liu | Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases |
WO2008109362A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting vegf gene expression and uses thereof |
WO2009045356A2 (en) * | 2007-09-28 | 2009-04-09 | Yale University | Microrna compositions in the treatment of vegf-mediated disorders |
US8188060B2 (en) * | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
AU2009221775B2 (en) * | 2008-03-05 | 2015-05-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 and VEGF genes |
MX2011005851A (es) * | 2008-12-04 | 2011-07-29 | Opko Opthalmics Llc | Composiciones y metodos para la inhibicion selectiva de isoformas vegf proangiogenicas. |
-
2011
- 2011-07-26 MX MX2013000986A patent/MX2013000986A/es not_active Application Discontinuation
- 2011-07-26 CA CA2804847A patent/CA2804847A1/en not_active Abandoned
- 2011-07-26 WO PCT/US2011/045273 patent/WO2012015775A2/en active Application Filing
- 2011-07-26 RU RU2013102545/10A patent/RU2013102545A/ru not_active Application Discontinuation
- 2011-07-26 AU AU2011282902A patent/AU2011282902B2/en not_active Ceased
- 2011-07-26 US US13/190,797 patent/US8546349B2/en active Active
- 2011-07-26 CN CN201180036639XA patent/CN103068981A/zh active Pending
- 2011-07-26 KR KR1020137004590A patent/KR20130095737A/ko not_active Application Discontinuation
- 2011-07-26 BR BR112013001918A patent/BR112013001918A2/pt not_active IP Right Cessation
- 2011-07-26 JP JP2013521887A patent/JP2013539456A/ja active Pending
- 2011-07-26 EP EP11813031.9A patent/EP2598639A4/en not_active Withdrawn
- 2011-07-27 TW TW100126492A patent/TW201219041A/zh unknown
- 2011-07-27 UY UY0001033533A patent/UY33533A/es not_active Application Discontinuation
- 2011-07-28 AR ARP110102737A patent/AR082411A1/es unknown
-
2013
- 2013-01-21 ZA ZA2013/00531A patent/ZA201300531B/en unknown
- 2013-01-24 CL CL2013000237A patent/CL2013000237A1/es unknown
- 2013-08-27 US US14/010,749 patent/US9150862B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8546349B2 (en) | 2013-10-01 |
WO2012015775A2 (en) | 2012-02-02 |
KR20130095737A (ko) | 2013-08-28 |
CL2013000237A1 (es) | 2014-03-21 |
JP2013539456A (ja) | 2013-10-24 |
US20120029051A1 (en) | 2012-02-02 |
US20140031414A1 (en) | 2014-01-30 |
EP2598639A2 (en) | 2013-06-05 |
BR112013001918A2 (pt) | 2016-05-24 |
WO2012015775A3 (en) | 2012-08-09 |
CN103068981A (zh) | 2013-04-24 |
CA2804847A1 (en) | 2012-02-02 |
MX2013000986A (es) | 2013-07-03 |
EP2598639A4 (en) | 2014-08-13 |
RU2013102545A (ru) | 2014-09-10 |
AU2011282902B2 (en) | 2015-01-29 |
AU2011282902A1 (en) | 2013-01-31 |
AR082411A1 (es) | 2012-12-05 |
TW201219041A (en) | 2012-05-16 |
US9150862B2 (en) | 2015-10-06 |
ZA201300531B (en) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33533A (es) | siRNA DIRIGIDO AL VEGFA Y A MÉTODOS DE TRATAMIENTO IN VIVO | |
MX2010005018A (es) | Tratamiento de complicaciones de nacimiento prematuro. | |
NZ701715A (en) | Means and methods for treating dlbcl | |
EA201301354A1 (ru) | Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками | |
EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
NZ602798A (en) | Treatment of sarcoidosis using placental stem cells | |
MX2019005130A (es) | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente. | |
EA201490509A1 (ru) | Биосовместимый катетер | |
TR201818927T4 (tr) | Kataterlerde İyileştirme | |
UY33956A (es) | Anticuerpo del factor antitisular humano y sus usos para tratar cáncer | |
BR112014017161A2 (pt) | dispositivo de oclusão implantável, método de fazer um dispositivo de oclusão implantável, dispositivo para limitar o fluxo de fluido e método para ocluir um lúmen num tecido corporal | |
WO2011002239A3 (ko) | 포유류의 유핵세포에서 유래된 마이크로베시클 및 이의 용도 | |
CL2012002326A1 (es) | Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana. | |
EA201101568A1 (ru) | Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta | |
MX357749B (es) | Tratamiento contra el dolor utilizando células madre placentarias. | |
CL2011002610A1 (es) | Metodo de terapia complementaria que comprende la administracion a un paciente con cancer luego de la cirugia definitiva de un antagonista especifico del factor de crecimiento endotelial vascular (vegf) durante mas de un ano; y kit. | |
PE20160538A1 (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi) | |
EA201590747A1 (ru) | Способы лечения с использованием аденовируса | |
AR082312A1 (es) | Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos | |
GEP201706716B (en) | Optimised subcutaneous therapeutic agents | |
MX2010006650A (es) | Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica. | |
TR201109999A2 (tr) | Trombositten zengin fibrin yapımı için tüp. | |
EA201390530A1 (ru) | Способ получения сополимера натрийкарбоксиметилцеллюлозы и госсипола и его применение в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями | |
EA201490201A1 (ru) | Выявление экспрессии гена prame при раковом заболевании | |
NZ702666A (en) | A method of weight reduction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20200813 |